Pierre Fabre Pharma GmbH
12
3
3
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
8.3%
1 terminated/withdrawn out of 12 trials
87.5%
+1.0% vs industry average
17%
2 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Surgical or Radiotherapeutic Intervention Concerning Large Singular Stable to Progressive Metastases in Patients With BRAFV600-mutated Melanoma Receiving Treatment With Encorafenib + Binimetinib
Role: collaborator
Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer
Role: collaborator
Real-life Pan-HER-blockade With Neratinib
Role: lead
Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
Role: collaborator
BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment
Role: lead
Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment
Role: lead
Metronomic Treatment With Daily Oral Vinorelbine as First-line Chemotherapy in Patients With Advanced/Metastatic Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Breast Cancer
Role: collaborator
Initial Oral Vinorelbine Dosing Schedules in Clinical Routine in Germany and Austria
Role: lead
Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer
Role: collaborator
JAVLOR® Online Non-Interventional Trial
Role: lead
Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)
Role: lead
Study for Patients With Non Small Cell Lung Cancer (NSCLC)
Role: collaborator
All 12 trials loaded